Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Psychiatric |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 4/21/2016 |
| Start Date: | September 2009 |
| End Date: | February 2012 |
Diagnostic Utility of ADHD by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials
The purpose of this research study is to study a device called an electroencephalograph
(EEG) in the diagnosis of treatment of attention deficit hyperactivity disorder (ADHD) in
adults. People with ADHD have symptoms such as difficulty sustaining attention, organizing,
and managing impulsivity. They can have trouble in school, at work, and at home. Subjects
with ADHD who participate in this study will be given a once daily stimulant medication
called osmotic release methylphenidate (Concerta) for 6 weeks, and have EEG testing done
before and after the treatment period. Subjects will perform a computer based cognitive task
during EEG testing. The U.S. Food and Drug Administration has approved osmotic release
methylphenidate (Concerta) for the treatment of ADHD in adults and children. Similar
procedures, without medication, will be performed with a sample of healthy adults without
ADHD.
(EEG) in the diagnosis of treatment of attention deficit hyperactivity disorder (ADHD) in
adults. People with ADHD have symptoms such as difficulty sustaining attention, organizing,
and managing impulsivity. They can have trouble in school, at work, and at home. Subjects
with ADHD who participate in this study will be given a once daily stimulant medication
called osmotic release methylphenidate (Concerta) for 6 weeks, and have EEG testing done
before and after the treatment period. Subjects will perform a computer based cognitive task
during EEG testing. The U.S. Food and Drug Administration has approved osmotic release
methylphenidate (Concerta) for the treatment of ADHD in adults and children. Similar
procedures, without medication, will be performed with a sample of healthy adults without
ADHD.
ADHD Subjects
Inclusion Criteria:
- Male and female outpatients, aged 18-55 years
- Subjects meeting full criteria for the diagnosis of DSM-IV (Diagnostic and
Statistical Manual, Version 4) Attention Deficit Hyperactivity Disorder (ADHD)
- Absence of pharmacological treatment for ADHD for at least one week.
- Right handedness
Exclusion Criteria:
- Any other current psychiatric or medical condition determined to be clinically
significant.
- Current use of psychotropics or any medication with clinically significant CNS
(Central Nervous System) effects.
- Mental retardation (IQ < 80).
- Significant sensory deficits such as deafness or blindness.
- Individuals with a history of substance dependence or abuse within the past 6 months.
- Pregnant or nursing females.
- Subjects with pre-existing structural cardiac abnormalities.
- Clinically significant abnormal laboratory values, electrocardiogram or blood
pressure reading
Healthy Control Subjects
Inclusion Criteria:
- Males and females, aged 18-55 years
- Subjects who do not meet full criteria for the diagnosis of DSM-IV Attention Deficit
Hyperactivity Disorder (ADHD), as determined by clinical evaluation and/or ADHD
module of structured diagnostic interview, completed by the study clinician.
- Right handedness
Exclusion Criteria:
- Any current psychiatric or medical condition determined to be clinically significant.
- Current use of psychotropics or any medication with clinically significant CNS
effects.
- Mental retardation (IQ < 80).
- Significant sensory deficits such as deafness or blindness.
We found this trial at
1
site
Click here to add this to my saved trials
